Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | ACACA | Q13085 | 3/20 | 0.35 |
| ▸ | BACE1 | P56817 | 11/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076232 | 0.89 | ACACB (0.32) | DPP4SLC6A4SLC6A3ACACBACACA | |
| SCHEMBL5432156 | 0.88 | BACE1 (0.36) | BACE1 | |
| SCHEMBL2886584 | 0.84 | ACACB (0.33) | DPP4ACACBACACABACE1 | |
| SCHEMBL5435809 | 0.82 | BACE1 (0.32) | ACACBACACABACE1 | |
| SCHEMBL2996875 | 0.82 | CNR2 (0.31) | ACACBACACA | |
| SCHEMBL5929431 | 0.78 | PDE7A (0.41) | — | |
| SCHEMBL1344157 | 0.78 | ACACB (0.39) | DPP4SLC6A4SLC6A3ACACBACACA | |
| SCHEMBL2525634 | 0.77 | ACACB (0.37) | DPP4SLC6A4SLC6A3ACACBACACA | |
| SCHEMBL16562510 | 0.76 | ACACB (0.34) | DPP4SLC6A4SLC6A3ACACBACACA | |
| SCHEMBL11025895 | 0.75 | ACACB (0.43) | DPP4SLC6A4SLC6A3ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244007-A1 | Cis-Alkoxyspiro-Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1706377-A1 | CIS-ALKOXYSPIRO-SUBSTITUTED TETRAMIC ACID DERIVATIVES | Bayer CropScience Aktiengesellschaft (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005066125-A1 | CIS-ALKOXYSPIRO-SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244007-A1 | Cis-Alkoxyspiro-Substituted Tetramic Acid Derivatives | AGXT, PAOX, DDT | DPP4 1094/4885SLC6A4 3220/4885SLC6A3 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.